Universal Technical Institute I (UTI) Stock Price & How to Invest

Universal Technical Institute, Inc. (NYSE: UTI) runs postsecondary vocational schools across two reportable segments. The legacy UTI segment trains students in automotive, diesel, motorcycle, marine, welding, CNC and related skilled trades, while the Concorde Career Colleges segment (acquired in 2022) offers allied health, dental, nursing, patient-care and diagnostic programs. The company generates revenue primarily from student tuition, much of it funded through federal Title IV financial aid, and it has been growing student starts and average full-time enrollment at both segments.

The investment picture is a growth-versus-margin trade-off. Revenue rose about 14% in fiscal 2025 (year ended September 30, 2025) to roughly $835.6 million, and management guided fiscal 2026 revenue to roughly $905 to $915 million. However, reported net income and operating income have fallen sharply in recent quarters because the company is spending roughly $40 million in fiscal 2026 on new campus launches and program expansions that dilute near-term profitability. The stock has re-rated to a premium multiple on the expectation that these investments mature into higher earnings, which also makes it sensitive to any enrollment slowdown, regulatory shift, or expansion misstep.

UTI depends heavily on federal Title IV student aid, so changes to financial-aid rules, gainful-employment regulations, or the 90/10 revenue rule could materially affect the business. Near-term profitability has already collapsed on expansion spending, and the stock's premium multiple leaves little room for disappointment if new campuses underperform or enrollment growth stalls. The for-profit education sector carries a history of regulatory scrutiny and reputational risk. Rising labor and real-estate costs can pressure margins, and an economic downturn can cut both ways on enrollment. Any softening in student starts or graduate placement rates would challenge the growth narrative underpinning the current valuation.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Universal Technical Institute I's investor relations page or your broker.

• Revenue (FY2025): ~$835.6M
• Revenue guidance (FY2026): ~$905-915M
• Net income (FY2025): ~$63M
• Adjusted EBITDA (FY2025): ~$126.5M
• Market cap: ~$2.3B
• P/E (trailing): ~45-52x

Fiscal 2025 revenue grew about 14% and net income rose roughly 50% to about $63 million. Fiscal 2026 guidance calls for revenue near $905 to $915 million but net income of only about $40 to $45 million, reflecting roughly $40 million of growth-investment spending. The premium P/E reflects investor expectations that campus expansion will lift future earnings.

There are three common ways to get UTI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so UTI sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where UTI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

UTI is an established, growing career-education operator whose stock trades on the bet that today's campus-expansion spending converts into durable earnings.

Whether UTI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is UTI a buy?, and where the stock could go from here in the UTI stock forecast.

For income investors, whether UTI pays a dividend and how the payout looks is covered in does UTI pay a dividend?